Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

Internal Hemorrhoids Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in the Treatment of Symptomatic Internal Hemorrhoids.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03335774
• Other study ID #: HDCS 1701 (formerly 1-2017)
• Status: Completed
• Phase: Phase 2
• Start date: February 12, 2019
• Est. completion date: March 5, 2021

Study information

• Verified date: August 2022
• Source: Nivagen Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids.

Description:

STUDY DESIGN: 25 mg hydrocortisone suppositories administered twice daily compared to a vehicle placebo in approximately 100 subjects with symptomatic internal hemorrhoids. Subjects will be randomized in a 1:1 ratio (Test product: placebo). The study will consist of 2 periods: 1. Treatment Period (2 weeks/ Days 1-14) 2. Follow-up Period (2 weeks/ Days 15-28) The visits are as follows: Visit 1 (Day 1 Baseline/Randomization) Visit 2 (Day 8±1, Interim Visit) Visit 3 (Day 15±2, End of Treatment Visit) Visit 4 (Day 29±3, End of Study Visit) ENDPOINTS: 1. Clinician Reported Outcome (ClinRO) - Anoscopy (Visits 1, 3). Anoscopy - Visual assessment of hemorrhoids. Video of the procedure will be recorded for blinded central reading and assessment 2. Patient Reported Outcome: Subjects will use Daily Diaries to record the time and date of each medication application, concomitant medication and adverse events. The subjects will complete the Subject Questionnaire at Visits 1, 2, 3 and 4 (or early termination) and daily between visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: March 5, 2021
• Est. primary completion date: March 5, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• internal hemorrhoids.
• hemorrhoidal bleeding.
• male or female aged 18 years and older.
• willing to forego the use of non-prescription (OTC) and prescription medication or procedures for the treatment of hemorrhoidal disease and/or pain for the duration of the study.
• agree to not change their diet during the study.

Exclusion Criteria:

• external hemorrhoids.
• using other OTC or prescription medications for treatment of hemorrhoidal disease and/or pain.
• pregnant or nursing female.
• received systemic glucocorticoids within the last 2 months prior to starting study.
• participated in an investigational drug study within 30 days prior to baseline.

Related Conditions & MeSH terms

• Hemorrhoids
• Internal Hemorrhoids

Intervention

Drug:
• Hydrocortisone Acetate Suppository, 25 mg (Nivagen)
One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
• Placebo (Vehicle) Suppository (Nivagen)
One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).

Locations

Country	Name	City	State
India	Clinical Research	Navi Mumbai	Maharashtra
United States	Clinical Research	Charlotte	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Nivagen Pharmaceuticals Inc.

Countries where clinical trial is conducted

United States,  India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in Swelling	Reduction in the swelling of internal hemorrhoid was measured by anoscopy. Visual assessment of hemorrhoids was performed at end of treatment. Video of the procedure will be recorded for blinded central reading and assessment. Swelling was graded on a scale from "0 - None" to "4 - Very Severe".; Numeric grades and their changes from baseline are summarized descriptively by visit and treatment group. Changes from baseline will be compared between the treatment groups. Mean difference between the groups and its 95% confidence interval will be displayed at Visit 4, along with the p-value from the two-sample t-test.	Day 15
Primary	Reduction in Itching Severity	Patient-reported outcome (PRO) was collated and analyzed by deploying the Internal Hemorrhoid Sign and Symptom Assessment (IHSSA) questionnaire. The patients updated the questionnaire on a daily basis between visits 1-5. Responses to each item were averaged across each period.; The mean score from the Screening period was considered the baseline score.; Mean scores and their changes from baseline were summarized.; Itching was scored from on 0-4 scale (0 =No itching, 1 = A little itching, 2 =Moderate itching, 3 = A lot of itching, 4 = Worst itching that you could imagine	Day 15

External Links

•   Nivagen Pharmaceuticals Inc.